Caribou Biosciences (CRBU) CLO awarded major equity grants, sells shares for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Caribou Biosciences Chief Legal Officer Barbara G. McClung reported both equity grants and a small share sale. She received a grant of options to purchase 202,500 shares of common stock and a separate grant of 45,000 restricted stock units, both awarded on February 20, 2026.
The options vest in equal monthly installments over 48 months until February 20, 2030, and the RSUs vest in four equal annual installments beginning February 20, 2027, contingent on continued service. On February 24, 2026, 6,938 shares were sold at $1.96 per share solely to cover tax withholding on previously vested RSUs under an existing Rule 10b5-1 sell-to-cover plan, leaving her with 481,564 common shares directly owned.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 6,938 shares ($13,598)
Net Sell
3 txns
Insider
MCCLUNG BARBARA G
Role
Chief Legal Officer
Sold
6,938 shs ($14K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,938 | $1.96 | $14K |
| Grant/Award | Option to purchase Common Stock | 202,500 | $0.00 | -- |
| Grant/Award | Common Stock | 45,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 481,564 shares (Direct);
Option to purchase Common Stock — 202,500 shares (Direct)
Footnotes (1)
- This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
FAQ
What equity awards did Caribou Biosciences (CRBU) grant to Barbara McClung?
Barbara McClung received options for 202,500 shares and 45,000 restricted stock units. The options were granted at a $0.00 exercise price and vest monthly over 48 months, while the RSUs vest in four equal annual installments starting February 20, 2027.
How do Barbara McClung’s new stock options at Caribou Biosciences (CRBU) vest?
The 202,500 stock options vest in 48 equal monthly installments. One forty-eighth of the total vests on each monthly anniversary of the February 20, 2026 grant date, so the option becomes fully vested on February 20, 2030, assuming continued service to Caribou Biosciences.
What are the vesting terms of Barbara McClung’s RSUs at Caribou Biosciences (CRBU)?
The 45,000 RSUs vest in four equal annual installments beginning February 20, 2027. Vesting requires that Barbara McClung continue providing service to Caribou Biosciences on each vesting date, and the RSUs settle in stock within 30 days after each vesting date.